NEW YORK (GenomeWeb News) – BGI-Shenzhen said today that it has completed its cash tender offer for Complete Genomics, setting the stage for the merger of the two firms to be finalized.

The offer, which has been delayed numerous times, expired at 11:59 EDT March 14. As of the expiration of the offer, the depositary for the offer indicated that 31.4 million shares, or 88 percent, of Complete's stock had been validly tendered and not withdrawn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.